Literature DB >> 2831813

In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide.

L D Liebowitz1, J Saunders, L J Chalkley, H J Koornhof.   

Abstract

Isolates of Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus faecium, and coagulase-positive and -negative staphylococci were investigated for their abilities, in vitro, to develop resistance to LY146032. Exposure of the organisms to incremental concentrations of LY146032 resulted in MICs 8- to 32-fold higher than those for the original isolates. After three passages on antibiotic-free medium, the high MICs were maintained for the coagulase-negative staphylococci and pneumococci, with a twofold decrease observed for the enterococci and a fourfold decrease observed for Staphylococcus aureus. The frequency of spontaneous emergence of resistance was highest with S. pneumoniae (1.2 X 10(-6) at 16 times the original MIC) and lowest with S. aureus (7.0 X 10(-10) at 8 times the original MIC). For bacteria For bacteria surviving time-kill studies MICs were also higher than were those for the original isolates. Exposure to LY146032 in vitro selected for strains with decreased susceptibilities to the antimicrobial agent. However, the emergence of resistance in vivo is unpredictable and can be evaluated only after prolonged clinical use of the drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831813      PMCID: PMC172091          DOI: 10.1128/AAC.32.1.24

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

2.  In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.

Authors:  P Huovinen; P Kotilainen
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

3.  In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; S Willey; E Reiszner; P G Spitzer; G Caputo; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

4.  Emergence of vancomycin resistance in coagulase-negative staphylococci.

Authors:  R S Schwalbe; J T Stapleton; P H Gilligan
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

5.  Teicoplanin-resistant coagulase-negative staphylococci.

Authors:  V Arioli; R Pallanza
Journal:  Lancet       Date:  1987-01-03       Impact factor: 79.321

6.  In vitro activity of LY146032 (daptomycin), a new peptolide.

Authors:  F Ehlert; H C Neu
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

7.  Penicillin-resistant variants of pneumococci.

Authors:  J B Gunnison; M A Fraher; E A Pelcher; E Jasetz
Journal:  Appl Microbiol       Date:  1968-02

8.  Streptococcus pneumoniae resistant to penicillin and chloramphenicol.

Authors:  P C Appelbaum; A Bhamjee; J N Scragg; A F Hallett; A J Bowen; R C Cooper
Journal:  Lancet       Date:  1977-11-12       Impact factor: 79.321

9.  In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.

Authors:  G M Eliopoulos; A E Moellering; E Reiszner; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

View more
  8 in total

1.  Resistance studies with daptomycin.

Authors:  J A Silverman; N Oliver; T Andrew; T Li
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Comparison of two techniques for measurement of in vitro killing kinetics of five antibiotics against Pseudomonas aeruginosa.

Authors:  D Lesage; F Delisle; G Richard; B Burghoffer; D Le Cunff; J C Petit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-05       Impact factor: 3.267

3.  Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach.

Authors:  Adrien Fischer; Soo-Jin Yang; Arnold S Bayer; Ali R Vaezzadeh; Sébastien Herzig; Ludwig Stenz; Myriam Girard; George Sakoulas; Alexander Scherl; Michael R Yeaman; Richard A Proctor; Jacques Schrenzel; Patrice François
Journal:  J Antimicrob Chemother       Date:  2011-05-28       Impact factor: 5.790

4.  Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  George Sakoulas; George M Eliopoulos; Jeff Alder; Claudie Thauvin Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.

Authors:  W Poeppl; S Tobudic; T Lingscheid; R Plasenzotti; N Kozakowski; H Lagler; A Georgopoulos; H Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

Review 6.  Resistance to vancomycin and teicoplanin: an emerging clinical problem.

Authors:  A P Johnson; A H Uttley; N Woodford; R C George
Journal:  Clin Microbiol Rev       Date:  1990-07       Impact factor: 26.132

7.  Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.

Authors:  D Shonekan; D Mildvan; S Handwerger
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

8.  Turbidimetric response of Staphylococcus aureus and Enterococcus faecalis to daptomycin.

Authors:  M C Wale; L J Wale; D Greenwood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.